| |
| |
|
| Insider
Information: |
Myszkowski Kenneth Allen |
| Relationship: |
Chief Financial Officer |
| City: |
Pasadena |
| State: |
CA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
1 |
|
| Direct
Shares |
400,600 |
|
|
Indirect Shares
|
0 |
|
|
| Direct
Value |
$8,861,272 |
|
|
|
Indirect Value
|
$0 |
|
|
| Total
Shares |
400,600 |
|
|
| Total
Value |
$8,861,272 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
4
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
4
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
-4.0
|
| Percentage
Gain/Loss : |
0.0%
|
 -111.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Arrowhead Pharmaceuticals Inc |
ARWR |
Chief Financial Officer |
2024-03-06 |
400,600 |
2010-08-27 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2024-03-06 |
4 |
S |
$35.19 |
$1,407,600 |
D/D |
(40,000) |
400,600 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2024-01-05 |
4 |
AS |
$34.04 |
$567,910 |
D/D |
(16,104) |
440,600 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2024-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
75,000 |
456,704 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-06-27 |
4 |
S |
$36.20 |
$543,000 |
D/D |
(15,000) |
381,704 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2023-01-04 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
396,704 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2022-12-29 |
4 |
AS |
$40.00 |
$1,225,000 |
D/D |
(30,625) |
336,704 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2022-01-05 |
4 |
AS |
$60.50 |
$2,467,941 |
D/D |
(40,000) |
464,005 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2022-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
504,005 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2021-01-12 |
4 |
S |
$81.00 |
$116,721 |
D/D |
(1,441) |
444,005 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2021-01-11 |
4 |
S |
$81.02 |
$939,589 |
D/D |
(11,597) |
445,446 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2021-01-06 |
4 |
AS |
$70.75 |
$2,218,477 |
D/D |
(30,625) |
457,043 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2021-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
60,000 |
487,668 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2020-11-09 |
4 |
AS |
$69.04 |
$3,018,071 |
D/D |
(43,505) |
427,668 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2020-11-09 |
4 |
OE |
$14.54 |
$632,563 |
D/D |
43,505 |
471,173 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2020-10-20 |
4 |
AS |
$54.04 |
$1,576,131 |
D/D |
(29,166) |
427,668 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2020-10-20 |
4 |
OE |
$6.15 |
$179,371 |
D/D |
29,166 |
456,834 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2020-02-25 |
4 |
OE |
$5.19 |
$384,145 |
D/D |
43,445 |
427,668 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2020-01-21 |
4 |
AS |
$47.07 |
$1,992,925 |
D/D |
(40,313) |
384,223 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2020-01-21 |
4 |
OE |
$5.19 |
$173,092 |
D/D |
33,351 |
424,536 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2020-01-06 |
4 |
AS |
$59.60 |
$1,202,201 |
D/D |
(20,000) |
391,185 |
0 |
% |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2020-01-01 |
4 |
A |
$0.00 |
$0 |
D/D |
85,000 |
411,185 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2019-11-05 |
4 |
OE |
$5.19 |
$65,648 |
D/D |
12,649 |
326,185 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2019-11-01 |
4 |
AS |
$40.56 |
$1,547,378 |
D/D |
(37,884) |
313,536 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2019-11-01 |
4 |
OE |
$7.75 |
$293,601 |
D/D |
37,884 |
351,420 |
0 |
- |
|
| ARWR |
Arrowhead Pharmaceuticals... |
Chief Financial Officer |
• – – |
2019-05-31 |
4 |
OE |
$4.60 |
$172,800 |
D/D |
35,000 |
313,536 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
